RCT in 108 participants with alcohol use disorder and obesity receiving CBT: once-weekly semaglutide 2.4 mg vs placebo for 26 weeks reduced heavy drinking days more (-41.1 vs -26.4 percentage points; difference -13.7, p=0.0015); GI adverse events were more frequent.
RCTn = 108
Klausen et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial